17-Hydroxyprogesterone Test · Blood

If you have unexplained acne, excess body hair, irregular periods, or fertility problems, your standard hormone panel may come back looking perfectly normal while the real culprit goes undetected. 17-OHP (17-hydroxyprogesterone) is a steroid your adrenal glands produce on the way to making cortisol. When the enzyme responsible for the next step in that pathway is sluggish or missing, 17-OHP backs up in your blood and gets rerouted into androgen (male-type hormone) production, causing symptoms that overlap heavily with polycystic ovary syndrome (PCOS) and other conditions.

The condition this test is designed to catch is called non-classic congenital adrenal hyperplasia, or NCAH, a genetic enzyme deficiency affecting roughly 1 in 25 people worldwide as carriers and about 4.2% of women with androgen excess symptoms. Unlike the severe form diagnosed at birth, non-classic CAH often hides in plain sight through adolescence and adulthood, misdiagnosed as PCOS or unexplained infertility for years. A single morning blood draw can start to sort this out.

What 17-OHP Actually Measures

Your adrenal glands sit on top of each kidney and act like a hormone assembly line. One of the most important products is cortisol, your body's main stress-response hormone. To build cortisol, your adrenals convert cholesterol through several intermediate steps. 17-OHP is one of those intermediates. An enzyme called 21-hydroxylase (CYP21A2) is supposed to convert 17-OHP into the next molecule on the path to cortisol.

When 21-hydroxylase works normally, 17-OHP gets processed efficiently and blood levels stay low. When the enzyme is partially or fully impaired, 17-OHP accumulates and overflows into an alternative route that produces androgens, including a potent form called DHT (dihydrotestosterone). This overflow is the root cause of symptoms in congenital adrenal hyperplasia.

Your adrenals are the primary source of 17-OHP, but the ovaries and testes also produce smaller amounts through shared hormone-building pathways. In men, serum 17-OHP also reflects testosterone production inside the testes, making it a useful window into testicular function during fertility treatment.

Why This Test Matters: Congenital Adrenal Hyperplasia

Congenital adrenal hyperplasia due to 21-hydroxylase deficiency is the single most common autosomal recessive (inherited from both parents) hormone disorder. It comes in two main forms. Classic CAH is severe, usually caught by newborn screening, and can cause life-threatening salt-wasting crises in the first weeks of life. Non-classic CAH (NCAH) is far milder and often goes unrecognized until puberty or adulthood.

Among women evaluated for androgen excess symptoms like hirsutism, acne, and irregular cycles, about 4.2% turn out to have NCAH rather than PCOS. The distinction matters because the two conditions call for different treatments and carry different implications for genetic counseling and family planning. A basal morning 17-OHP level is the recommended first step to tell them apart.

In children, elevated 17-OHP can explain premature development of pubic hair, rapid growth that paradoxically leads to short adult height (because excess androgens close growth plates early), and ambiguous genitalia in severe cases. In adults, it can explain treatment-resistant acne, thinning scalp hair with excess body hair, and difficulty conceiving.

Male Fertility and Intratesticular Testosterone

Beyond CAH, 17-OHP has an emerging role in men's reproductive health. In a prospective study evaluating 140 men, serum 17-OHP strongly correlated with testosterone levels inside the testes, which cannot be measured directly without a biopsy. Men on exogenous testosterone replacement had 17-OHP levels that were often undetectable, reflecting near-complete shutdown of the testes' own hormone production. Men taking fertility-preserving medications like clomiphene or hCG (human chorionic gonadotropin) had 17-OHP levels roughly double their baseline after three months.

If you are a man on testosterone therapy considering having children, or if you are taking clomiphene or hCG to support fertility, 17-OHP can serve as a practical, noninvasive way to check whether your testes are actually producing testosterone on their own.

Diagnostic Accuracy

For detecting non-classic CAH in women with androgen excess, a morning 17-OHP level drawn during the follicular phase (the first half of the menstrual cycle) above 2 ng/mL (6 nmol/L) has sensitivity near 100%. Specificity varies by cutoff and assay: one study found 88.6% specificity at a threshold of 1.7 ng/mL, while higher cutoffs and newer assays can approach 100%. A level at or above 10 ng/mL (30 nmol/L), either at baseline or after an ACTH stimulation test (a short injection that maximally stimulates the adrenals), is considered diagnostic.

However, 17-OHP alone cannot always distinguish between someone who carries one copy of the gene mutation (a carrier, who is healthy) and someone with two copies (who has NCAH). When values fall in an intermediate zone, ACTH stimulation testing and sometimes genetic testing of the CYP21A2 gene are needed to clarify. Newer multi-steroid panels measured by liquid chromatography-tandem mass spectrometry (LC-MS/MS, a highly precise lab technique), which includes a molecule called 21-deoxycortisol alongside 17-OHP, can achieve 100% sensitivity and near-100% specificity for NCAH, even without the ACTH stimulation step.

Reference Ranges

17-OHP levels depend heavily on time of day, sex, menstrual cycle phase, and age. The ranges below reflect published clinical thresholds used for diagnostic purposes, not general wellness optimization. There are no established "optimal" or "longevity" targets for this biomarker. These values apply to morning, follicular-phase blood draws in adults using standard immunoassay methods. Your lab may report slightly different numbers depending on the assay platform.

For newborn screening, cutoffs are adjusted by gestational age rather than birth weight, because gestational age explains about 50.6% of the variation in neonatal 17-OHP levels. Preterm infants routinely produce higher levels that can trigger false positives.

When Results Can Be Misleading

17-OHP follows a strong circadian rhythm, paralleling cortisol. Levels are highest in the early morning and can drop substantially by afternoon or evening. Drawing blood at the wrong time of day is the single most common reason for a misleading result. For women, testing during the luteal phase (second half of the menstrual cycle) can produce elevated values that mimic NCAH.

In newborns and preterm infants, standard lab methods (immunoassays) can overestimate 17-OHP because they partially detect other steroids that look chemically similar, a problem especially common when those other steroids are present at high concentrations in immature adrenal glands. One study found that the commonly used Delfia screening test overestimates 17-OHP in preterm infants, making it unreliable for determining CAH risk in that population without second-tier confirmation.

Several medications shift 17-OHP without causing CAH. Exogenous testosterone therapy can suppress 17-OHP to near zero by shutting down testicular production, while hCG or clomiphene can double it by stimulating the testes. If you are taking any hormone therapy, your results must be interpreted in that context. Combined oral contraceptives appear to have minimal effect on 17-OHP at the group level.

Body composition also plays a role. In a study of young men, higher body fat, larger waist circumference, and greater insulin resistance were each independently associated with lower 17-OHP, even after accounting for LH levels. A single mildly abnormal result near a diagnostic cutoff should always be confirmed with a repeat morning sample under standardized conditions.

Tracking Your Trend

Because 17-OHP has a within-person biological variation of approximately 23% from week to week, and intraday swings can be even larger, a single reading near a borderline threshold is not enough to act on. If your first result is in the 2 to 10 ng/mL range, repeat the test on a different morning, ideally in the early follicular phase if you menstruate, before pursuing further workup.

For people already diagnosed with CAH and on glucocorticoid (cortisol-replacing steroid medication) therapy, serial 17-OHP measurements are essential for dose adjustment. In a two-year study of young children with CAH, 17-OHP measurements (mostly from saliva samples) guided hydrocortisone dose changes at 27% of clinic visits, maintaining adrenal control while avoiding overtreatment. The goal is not to drive 17-OHP to zero, which would mean excessive glucocorticoid dosing, but to keep it in a range that prevents androgen excess without causing side effects from overreplacement.

If you are tracking 17-OHP over time, always use the same lab and the same collection conditions (same time of morning, same point in your menstrual cycle). Comparing results across different labs or assay methods introduces noise that can obscure real trends.

What to Do With an Abnormal Result

If your 17-OHP comes back above 2 ng/mL on a properly timed morning draw, the next step is an ACTH stimulation test, where a synthetic version of the pituitary hormone ACTH is injected and 17-OHP is measured 30 to 60 minutes later. A stimulated value at or above 10 ng/mL confirms NCAH with high confidence.

Companion tests that add context include cortisol (to assess whether your adrenals can make enough), androstenedione and total testosterone (to quantify the degree of androgen overflow), and DHEA-S (dehydroepiandrosterone sulfate, another adrenal androgen). If NCAH is confirmed, CYP21A2 genotyping is recommended for genetic counseling, especially if you are planning a pregnancy, because two carrier parents have a 25% chance of having a child with classic CAH.

For men being evaluated for fertility, a very low or undetectable 17-OHP while on testosterone therapy confirms that testicular production has shut down. If you are trying to conceive, this result supports switching to a fertility-preserving regimen like clomiphene or hCG, and 17-OHP can be used to confirm that the testes have started making their own testosterone again. An endocrinologist or reproductive urologist is the right specialist for this workup.